Pluristem Therapeutics (NASDAQ: PSTI) and Momenta Pharmaceuticals (NASDAQ:MNTA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and profitability.
This is a summary of recent recommendations and price targets for Pluristem Therapeutics and Momenta Pharmaceuticals, as provided by MarketBeat.com.
||Strong Buy Ratings
Pluristem Therapeutics currently has a consensus price target of $4.00, indicating a potential upside of 225.20%. Momenta Pharmaceuticals has a consensus price target of $15.63, indicating a potential downside of 31.32%. Given Pluristem Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe Pluristem Therapeutics is more favorable than Momenta Pharmaceuticals.
Volatility and Risk
Pluristem Therapeutics has a beta of 0.28, suggesting that its share price is 72% less volatile than the S&P 500. Comparatively, Momenta Pharmaceuticals has a beta of 1.65, suggesting that its share price is 65% more volatile than the S&P 500.
Institutional and Insider Ownership
4.0% of Pluristem Therapeutics shares are held by institutional investors. Comparatively, 94.8% of Momenta Pharmaceuticals shares are held by institutional investors. 7.2% of Pluristem Therapeutics shares are held by insiders. Comparatively, 4.8% of Momenta Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This table compares Pluristem Therapeutics and Momenta Pharmaceuticals’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Valuation & Earnings
This table compares Pluristem Therapeutics and Momenta Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.
||Earnings Per Share
Pluristem Therapeutics has higher earnings, but lower revenue than Momenta Pharmaceuticals. Momenta Pharmaceuticals is trading at a lower price-to-earnings ratio than Pluristem Therapeutics, indicating that it is currently the more affordable of the two stocks.
Pluristem Therapeutics beats Momenta Pharmaceuticals on 8 of the 13 factors compared between the two stocks.
Pluristem Therapeutics Company Profile
Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops PLacental eXpanded (PLX) cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients ineligible for revascularization, recovery after surgery for femoral neck fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases. It also develops PLX-R18 cells that is in Phase I clinical trial for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various in-vivo studies for the evaluation of PLX-R18 for the treatment of ARS. The company has collaborative research agreement with the Berlin-Brandenburg Center for Regenerative Therapies; and a license and commercialization agreement for conducting clinical trials and commercialization of its PLX-PAD product in South Korea related to the treatment CLI and intermediate claudication. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.
Momenta Pharmaceuticals Company Profile
Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The company's complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE. Its biosimilars programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M834, a biosimilar of ORENCIA for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis, as well as other biosimilar candidates. The company's novel therapeutics programs include M254, a hyper-sialylated version of intravenous immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy; M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; and M230, a recombinant trivalent human IgG1 Fc multimer to block tissue damage mediated by immune complexes. It has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.